Biocompatibles Share Discussion Threads

[plutonian] 10/1/2007 08:56

2006 Results:
* Revenue of £6.0m, representing growth of 76% on 2005; and compared with
most recent guidance of £5.5m to £6.5m(1).
* Year-end net funds of £37.2m compared with most recent guidance of £34m(1).
Selected 2007 Goals include:
Biocompatibles Bead Programmes
* Launch of DC Bead in China
* PRECISION V Interim analysis
* Recruitment of first patient into PRECISION IV survival trial
* IDE approval of Irinotecan Bead in Phase IIb, mCRC trial

CellMed Programmes
* Start of CE Mark trial for the cosmetic bead
* Start of Phase I/II trial in stroke
* Out-licence of CellMed peptide

2007 Guidance:
* Revenue in the range £8m to £10m.
* Closing net funds of £30m.

[plutonian] 28/12/2006 16:27

Quite a lot of news recently:

PRECISION I clinical trial - Positive results
Acquisition of CellMed confirmed - Revenues up this year
Application for Stroke Trial Submitted by Cellmed
Regulatory application in China for DC Bead - biggest HCC market by far

and more to come...
In the first half of January, the Company will provide a preliminary estimate of 2006 sales and guidance on the key financial items and the operational goals for 2007.

[2bob] 02/11/2006 22:35

Data Presented by Independent Physician Panel Confirms Low Rate of Thrombosis with Medtronic Endeavor Drug-Eluting Sten

[sweetiepye] 20/10/2006 21:49

hi yall

oops - what happened this time ? could it be that no news is bad news ?

nite nite

[sweetiepye] 11/10/2006 12:00

hi yall and 2bob

i know the post is poor but even 2nd class should have delivered interims before today - having regard to last week's announcement i wonder when they were posted ?

bi bi

[2bob] 03/10/2006 21:33

What the BII release does not mention is the status of the Abbott research agreement. One assumes that is all dead. If all the Abbott agreements are now terminated that will mean that Abbott will no longer put a protective arm around BII to deter predators. This has prevented advances from Lombard Medical in the past. Time to consider again merging BII into Lombard or BII making a bid for the Polybiomed division to give more ballast to their offering.

[cornelious billy bee] 03/10/2006 20:49

Plutonian - 22 Sep'06 - 14:50 - 95 of 104


LONDON (AFX) - Biocompatibles International PLC said managing director Dr. Peter Stratford and his wife sold a total of 26,604 shares at 194.65p each and
now hold 660 shares.

well I never, a director selling before bad news...

[graham142] 03/10/2006 17:19

A lot of us thought we had been screwed at the time of the deal with abbott and weren't happy with it - now they turn the knife....
The FSA should take a look at the recent MD transaction - but don't hold your breath.

[scrapheap] 03/10/2006 15:18

Interesting that the MD and his wife sold nearly all their shares just before this news came out from Abbott!!!!

[the count] 03/10/2006 14:45

THE COUNT--->2BOB

Just checked with my broker and was typing my post above while you dug up the news. Our posts have crossed. I guess it's too late to save the bulk of anyone's investement now but at least people now know the reason.

Regards,

THE COUNT!

[the count] 03/10/2006 14:43

THE COUNT--->ALL

I don't follow these any more but I noticed the fall today despite there being no announcement from the company.

I have heard news from elsewhere that it is down to Abbott abandoning BII's drug eluting stent technology.

I have not seen the full details of the announcement from ABBOTT so double check the wording before anyone does anything drastic....although the price fall says it all I guess.

Regards,

THE COUNT!

[2bob] 03/10/2006 14:42

Abbott release today


Focus on XIENCE V

After analyzing the clinical data from both the XIENCE V and ZoMaxx programs, Abbott has determined that it will not pursue commercialization of ZoMaxx, and will instead focus its commercial, manufacturing and clinical resources on XIENCE V. Nine-month clinical data from ZOMAXX I, Abbott's international ZoMaxx trial, will be presented at the Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington D.C. on October 23, 2006.

"We have conducted a thorough analysis of all available clinical data for both XIENCE V and ZoMaxx, and have concluded that XIENCE V is a significantly better product," said Richard A. Gonzalez, president and chief operating officer, Abbott. "Following encouraging physician feedback from our pre- launch evaluation program in Europe, and given the positive XIENCE V data, we remain confident in our ability to achieve a leadership position in the drug- eluting stent market with the XIENCE V platform."

Abbott recently announced that it is expanding its drug-eluting stent manufacturing capacity in Ireland to prepare for future launches in the U.S. and Japan.

"Abbott is pleased to offer XIENCE V as a new treatment option to European physicians for patients with coronary artery disease, which remains a leading cause of death around the world," Capek said. "As a leader in vascular care, Abbott will continue to deliver on its commitment to provide innovative technologies to advance the treatment of vascular disease


##########
Thanks TC

[graham142] 27/9/2006 21:34

cheers mate... Hic!

[graham142] 27/9/2006 21:34

Maybe he needs to stock up the drinks cabinet for Xmas ...

[scribbler101] 25/9/2006 19:57

Seems odd though - surely £50k can't be a lot to him?

Has anyone phoned the co and asked why he sold?

[tratante] 25/9/2006 15:19

Directors sale doesn't seem to have harmed the share price still on an upward trend.

[plutonian] 22/9/2006 14:50

LONDON (AFX) - Biocompatibles International PLC said managing director Dr. Peter Stratford and his wife sold a total of 26,604 shares at 194.65p each and
now hold 660 shares.

[dadesarno_d] 21/9/2006 18:56

Superb read:

This is an awesome find & it is totally free. This newsletter has an excellent track record. It profiles undervalued stocks with huge potential. It is sent to your e-mail every couple of weeks. Check it out!

[scribbler101] 21/9/2006 18:16

Well, IC does have a certain reputation!

[graham142] 18/9/2006 20:30

Small write up in investors chronicle this month - positive...

[plutonian] 12/9/2006 14:42

Positive Data from Second Drug Eluting Bead Programme for the Treatment of Metastatic Colorectal Cancer

[plutonian] 12/9/2006 14:39

Interims - 21 Sep 2006

[tratante] 12/9/2006 13:05

The patient is waking up!